Trial Profile
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in Nonalcoholic Steatohepatitis (NASH) Treatment (FLINT) Trial
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Dec 2022
Price :
$35
*
At a glance
- Drugs Obeticholic acid (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Acronyms FLINT
- 08 Nov 2022 Results assessing the respon-siveness of the score to detect changes in fibrosis longitudinally, by interrogating the Farnesoid X nuclear receptor ligand obeticholic acid for non- alcoholic steatohepatitis, presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases.
- 08 Nov 2022 Results (n=200) assessing whether the elevated serum alkaline phosphatase represents a marker of a unique phenotype of non-alcoholic fatty liver disease, presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases.
- 08 Nov 2022 Results (n=76) assessing the relationship between reduction in adipose tissue compartment volumes and hepatic histologic improvement, published in the Journal of Hepatology.